



**BioLight Life Sciences Ltd.**

(The "Company")

July 20<sup>th</sup>, 2023

**DiagnosTear Ltd., a subsidiary of the Company, to engage in a cooperation agreement for the use of its TeaRx™ Technology in clinical trials.**

The Company is honored to announce that its subsidiary, DiagnosTear Ltd. ("**DiagnosTear**") which develops the TeaRx™ Technology designed for the identification, diagnosis, adjustment of treatment, and follow-up of diseases in the front of the eye by examining the composition of the tear fluid ("**TeaRx™ product**") has informed the Company, that it has entered into a cooperation agreement with Lexitas Pharma Services, Inc., one of the largest companies operating in the USA for the management of clinical studies in the field of eyes ("**Lexitas**" and "**The Cooperation Agreement**", respectively). As part of the cooperation agreement, Lexitas will offer its potential customers who are in clinical research trials for the treatment of diseases in the front of the eye ("**the clinical research invitees**"), to include the TeaRx™ Technology and its product as part of their clinical trials.

According to DiagnosTear, the use of the TeaRx™ product in clinical trials may improve the number of recruited patients within these clinical trials. In addition, the TeaRx™ product has the potential to monitor the progress of the disease and support the action of the medical treatment being administered.

In the event that the clinical research invitees will use the TeaRx™ product in the framework of their research, DiagnosTear will be entitled to compensation as will be agreed with Lexitas. In addition, for each clinical research invitees that will be interested in using the TeaRx™ technology for additional research, or for commercial purposes, DiagnosTear and the clinical research invitees will enter into a separate agreement for the use of TeaRx™ and/or the development of a dedicated product based on the TeaRx™ technology in accordance with commercial conditions that will be established in future negotiations between the parties.

As reported to the Company, Lexitas is one of the largest companies operating in the US for the management of clinical studies (CRO) in the field of ophthalmology, managing over 30 clinical trials per year, with over 200 employees throughout the US, Canada, and Europe.

**Forward-looking Statement** - The information stated in this report in connection with participation in clinical studies within the framework of the cooperation agreement and/or signing of future cooperation agreements, either for the use of the TeaRx™ product or for the development of a dedicated product based on the TeaRx™ Technology, including estimates regarding its scope and/or contribution to the development of Diagnostear's activity, constitute forward-looking statements as defined in the Securities Law, H-1968, which involves uncertainty, and which may or may not materialize or materialize in a different way (including substantially) than described above, for reasons beyond the control of DiagnosTear and/or the other parties as mentioned.

*Free translation: non-binding.*

*This is a translated version of the Company's immediate report in Hebrew as filed with the Israeli SEC – created for convenience purposes only. In case of contradiction, the Hebrew version will take precedence.*